Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise

UCB Pharma687 enrolled

Overview

This non-interventional observational study is designed to gain data for Neupro® in restless legs syndrome (RLS) under real life conditions in line with the summary of product characteristics (SmPC) related to effectiveness, tolerability and switching practice from other dopaminergic drugs as well as titration schemes.

There is a total of 64 subjects recorded as having discontinued due to Adverse Events. Documentation of Visit 2 and Visit 3, where the reason for discontinuation was documented, was not available for all subjects. From the documentation on the Adverse Events page in the Case Report Form, it is known that 100 subjects discontinued due to Adverse Events. The Last Observation Carried Forward (LOCF) method was utilized for all outcomes.

Study Type

OBSERVATIONAL

Enrollment

687

Conditions

Idiopathic Restless Legs Syndrome

Interventions

Neupro®DRUG

Neupro® is the exposure/intervention of interest in this non-interventional study.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * It was recommended that the patient's treatment was in accordance with the local marketing authorization (MA) for Neupro® * The patient must have a diagnosis of moderate to severe idiopathic RLS * The patient is considered reliable and capable of adhering to the visit schedule or medication administration according to the judgment of the investigator * The decision to prescribe the drug has been made by the physician independently of his/her decision to include the patient in the study * Subject is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent Exclusion Criteria: * Hypersensitivity to the active substance or to any of the excipients * Magnetic resonance imaging or cardioversion (see SmPC)

Locations (80)

Outcomes

Primary Outcomes

Severity of Restless Legs Syndrome (RLS) at Bedtime

Severity of RLS at bedtime measured as change from baseline to end of observation period (Item 2 RLS-6 scale). The Last Observation Carried Forward (LOCF) method was utilized for all outcomes. The RLS-6 scale is an 11-point scale (from 0 = not present/completely satisfied to 10 = very severe/completely dissatisfied) to establish an individual severity profile at various day and night times (at bedtime; during the night; during the day when the patients are resting, or during the day when the patients are involved in daily activities).

Time frame: From Baseline to end of Observation Period (3 months).

Severity of Restless Legs Syndrome (RLS) During the Night

Severity of RLS during the night measured as change from baseline to end of observation period (Item 3 RLS-6 scale). The Last Observation Carried Forward (LOCF) method was utilized for all outcomes. The RLS-6 scale is an 11-point scale (from 0 = not present/completely satisfied to 10 = very severe/completely dissatisfied) to establish an individual severity profile at various day and night times (at bedtime; during the night; during the day when the patients are resting, or during the day when the patients are involved in daily activities).

Time frame: From Baseline to end of Observation Period (3 months).

Secondary Outcomes

Satisfaction With Sleep

Satisfaction with sleep measured as change from baseline to end of observation period (Item 1 RLS-6 scale). The Last Observation Carried Forward (LOCF) method was utilized for all outcomes. The RLS-6 scale is an 11-point scale (from 0 = not present/completely satisfied to 10 = very severe/completely dissatisfied) to establish an individual severity profile at various day and night times (at bedtime; during the night; during the day when the patients are resting, or during the day when the patients are involved in daily activities).

Time frame: From Baseline to end of Observation Period (3 months).

Severity of Restless Legs Syndrome (RLS) at Daytime at Rest

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Abensburg, Germany

Unnamed facility

Altenholz, Germany

Unnamed facility

Alzenau in Unterfranken, Germany

Unnamed facility

Anklam, Germany

Unnamed facility

Aschaffenburg, Germany

Unnamed facility

Bad Neustadt an der Saale, Germany

Unnamed facility

Berlin, Germany

Unnamed facility

Bielefeld, Germany

Unnamed facility

Bischofswerda, Germany

Unnamed facility

Bochum, Germany

...and 70 more locations